Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Search by Keyword
Sort By
  • Hans Popper Basic Science SOA: Gut Microbiota and Liver

    Contains 2 Component(s) Recorded On: 10/23/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    The intestinal microbiota and the human body have a symbiotic relationship, and a dysbalance of this delicate homeostasis can lead to disease. Liver diseases are associated with changes in the gut microbiota. Intestinal dysbiosis is characterized by bacterial overgrowth and changes in the microbiota composition. In addition, most chronic liver diseases are associated with intestinal barrier dysfunction. The contribution of intestinal dysbiosis to chronic liver disease goes beyond disruption of the intestinal barrier. Microbial metabolites are equally important for the progression of liver disease. Better understanding of host-microbial interactions will allow discovery of novel therapeutic targets in the gut microbiota, enabling new treatment options that restore the intestinal ecosystem precisely and influence liver disease. This session will review beneficial aspects of the microbiome for human health. Attendees will learn how to characterize changes of the gut microbiota associated with liver disease and their contributions to disease progression. Additionally, the session will cover modulation options of the gut microbiota to improve liver disease treatment. 

    Gavin E. Arteel

    Bernd Schnabl

  • Hepatobiliary Neoplasia SIG: HCV Therapy and HCC

    Product not yet rated Contains 8 Component(s) Recorded On: 10/23/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    This program provides a timely review of the mechanistic and clinical information relevant to HCC occurring in HCV by addressing the relevance of the problem and treatment effects. The program will also discuss key basic concepts with relevance to HCC in HCV.

    Gregory J. Gores

    Augusto Villanueva

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

    Hashem B. El-Serag

    Nathalie G. Carrie

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Maria Reig

    Amit G. Singal

    Dr. Singal completed his GI and transplant hepatology fellowships at the University of Michigan and is currently an Associate Professor of Medicine at UT Southwestern Medical Center in Dallas. He serves as Clinical Chief of Hepatology and Medical Director of the UT Southwestern and Parkland Memorial Liver Tumor programs. He has over 75 peer-reviewed publications, with the majority examining the hepatocellular carcinoma screening process, from risk assessment to early detection to treatment. 

    Laura M. Kulik

  • HCV 2017 Treatment Symposium

    Product not yet rated Contains 5 Component(s) Recorded On: 10/23/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    This program will include discussions of recently approved regimens and challenging patient populations.  The emphasis in these lectures will be on clinical knowledge and application to individual patient management decisions, the AASLD-IDSA Guidance Panel treatment recommendations, and global perspectives on disease eradication strategies.

    Andrew J. Muir

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

    Susanna Naggie

    Philippa Easterbrook

    Paul Y. Kwo

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

    Paul J. Pockros

  • Advances for Practitioners: Cholestatic and Autoimmune Liver Disease

    Product not yet rated Contains 3 Component(s) Recorded On: 10/23/2017

    AASLD's Advances for Practitioners presented at The Liver Meeting® 2017.

    This session will highlight recent key studies in the field of cholestatic and autoimmune liver diseases. Speakers will review data on new therapies for the treatment of PBC and discuss the role of risk stratification in the management of this disease. Additionally, recent studies evaluating new biomarkers and surveillance strategies in PSC will be reviewed to determine their usefulness and applicability. Finally, the session will evaluate the evidence underlying the use of specific second line therapies in autoimmune hepatitis and a treatment algorithm will be proposed.

    Christopher L. Bowlus

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Christoph Schramm

    John M. Vierling

  • 2017 Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease

    Product not yet rated Contains 7 Component(s) Recorded On: 10/23/2017

    AASLD's Global Forum presented at The Liver Meeting® 2017.

    NAFLD affects 24% of the adult population worldwide. Additionally, about 10% of children and adolescents may have NAFLD. NAFLD is closely associated with type 2 diabetes and obesity. A proportion of subjects with NAFLD and non-alcoholic steatohepatitis (NASH) can develop progressive liver disease, cirrhosis and liver cancer. There are extensive efforts to develop non-invasive tests for NASH. Although no approved therapeutic options for NASH are yet available, a large number of clinical trials are underway. This forum will review, in all pertinent regions of the world, the current state of NAFLD with regard to its clinical and epidemiologic burden and discuss knowledge gaps, unmet needs and current clinical practice.  A secondary focus will be to foster global collaboration and exchange to reach a common objective to improve patient outcomes, decrease disease burden by NAFLD and how to prevent and treat NAFLD throughout the world.

    Zobair M. Younossi

    Frank Tacke

    Barjesh C. Sharma

    Marco Arrese

    Hisham R. El Khayat

    Miriam B. Vos

  • AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease

    Contains 5 Component(s) Recorded On: 10/23/2017

    AASLD's AASLD/EASL Symposium presented at The Liver Meeting® 2017.

    The Symposium will provide a broad overview on the diversity of noninvasive diagnostic approaches for assessing chronic liver disease in the U.S. and Europe. Experts will discuss the role and interpretation of noninvasive diagnostic test strategies in assessing the severity of disease associated with NAFLD, cirrhosis, and portal hypertension. These lectures — in conjunction with a panel discussion — will benefit all healthcare professionals using these novel tools in their clinical practice.  

    Jayant A. Talwalker

    Sumeet K. Asrani

    Massimo Pinzani

    Rohit Loomba

    Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.

    Laurent Castera

  • Basic Research Workshop: A New Era of Gene Editing for Liver Disease

    Product not yet rated Contains 8 Component(s) Recorded On: 10/22/2017

    AASLD's Basic Research Workshop presented at The Liver Meeting® 2017.

    The future is bright for the continued development of novel gene therapy approaches in liver disease. But, a deeper understanding of off-target effects and immune responses generated in host cells by gene carriers is needed to fully realize their potential. This workshop will provide an overview of current and emerging therapeutic gene editing strategies for liver diseases. Speakers will discuss how novel genome editing techniques and designer nucleases offer the ability to carry out sophisticated gene function studies in vivo. In addition, the workshop will look at how the refinement of delivery systems is paving the way for the translation of gene therapy from bench to bedside.

    Clifford Steer

    R. Scott Mclvor

    Wen Xue

    Mark A. Kay

    Christian Mueller

    Lili Wang

    Keith R. Jerome

  • Thomas E. Starzl Transplant SOA: Equity in Access to Organ Allocation

    Product not yet rated Contains 2 Component(s) Recorded On: 10/22/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    As the U.S. continues to face disparities in organ allocation — due to an imbalance of supply and demand — patients who are on the waitlist for liver transplantation are increasingly at risk. This session will discuss the importance of geographic disparities in liver transplantation as well as various strategies proposed to address this critical issue in healthcare. 

    Julie Heimbach

    John R. Lake

  • Clinical Practice SIG: Best Practices in Clinical Hepatology

    Contains 3 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Identifying best practices in the difficult management of patients with liver disease in the community outpatient setting is an important topic in clinical hepatology. It is particularly important to look at the approach to patients with non-alcoholic liver disease that are not  candidates for research studies, the management of portal hypertension and portal vein thrombosis, and outpatient intervention and monitoring of patients with cirrhosis and renal insufficiency. The emphasis of this program is to provide tools for community practitioners to develop management strategies for better patient outcomes. Speakers will review a multidisciplinary approach to these problems and demonstrate the benefit of working in a team that — according to the problem in question — may include surgeons, oncologists, hematologists, nephrologists, interventional radiologists and nutrition experts.

    Kris V. Kowdley

    Mitchell L. Shiffman

    Marcelo Kugelmas

  • Cholestatic and Biliary Diseases SIG: Novel Treatment Approached to Cholestatic Liver Diseases: Theory and Practice

    Product not yet rated Contains 9 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Recently there is an increased interest and effort in targeting novel pathways to treat cholestatic liver diseases.  Up-to-date science is needed on the new therapeutic targets and the early experiences (successes and failures) of clinical trials to foster discussion of these various approaches and identify priorities for future clinical trials. Presentations in this program will be arranged in pairs with the first explaining the science behind why a specific pathway has good targets for treating cholestatic liver disease, followed by a summary of recent clinical trial and other descriptive experiences targeting these pathways. Further discussion after the paired talks will address why drugs did or did not perform as expected in humans, along with planning priorities for future trials.

    Mario Strazzabosco

    Michael Trauner

    Saul J. Karpen

    Marina G. Silveira

    Marlyn J. Mayo

    Gideon Hirschfield

    Bart Staels

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    James H. Tabibian